{"filing":{"accession_number":"0001193125-26-333853","cik":"0002012593","ticker":"RAPP","company_name":"Rapport Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"rapp-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-20260805.htm"},"events":[{"id":24485,"run_id":22188,"accession_number":"0001193125-26-333853","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 filed under Item 2.02. The disclosure includes financial results (net loss of $56.6M, R\u0026D expenses of $51.4M, cash position of $436.1M), condensed consolidated financial statements, and business highlights regarding clinical trial progress for RAP-219 and pipeline advancement. The press release is furnished as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.","company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25048,"accession_number":"0001193125-26-333853","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 filed under Item 2.02. The disclosure includes financial results (net loss of $56.6M, R\u0026D expenses of $51.4M, cash position of $436.1M), condensed consolidated financial statements, and business highlights regarding clinical trial progress for RAP-219 and pipeline advancement. The press release is furnished as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:39:40.409068+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25048,"accession_number":"0001193125-26-333853","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 filed under Item 2.02. The disclosure includes financial results (net loss of $56.6M, R\u0026D expenses of $51.4M, cash position of $436.1M), condensed consolidated financial statements, and business highlights regarding clinical trial progress for RAP-219 and pipeline advancement. The press release is furnished as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:39:40.409068+00:00","company_name":"Rapport Therapeutics, Inc.","ticker":"RAPP","filing_date":"2026-08-05"}]}